Myocardial ischemia is a condition where there is insufficient blood flow within the heart muscle. Generx represents a new therapeutic class of biologics designed to promote angiogenesis, a natural process of blood vessel growth within the heart muscle, following a one-time intracoronary administration from a standard cardiac infusion catheter.
“Generx is the first and only DNA-based cardiovascular therapeutic to be advanced to phase III, and is believed to be the only current phase III product candidate for the potential treatment of stable angina, a chronic medical condition affecting millions of patients in the US and elsewhere,” stated Christopher Reinhard, Cardium’s chairman and CEO.
The phase III clinical study is expected to be underway in the first quarter of 2007. An additional follow-up study of Generx in men with recurrent angina due to myocardial ischemia is expected to commence later.